UNSPSC 51112009: Sunitinib

This classification denotes a tyrosine kinase inhibitor and angiogenesis activator inhibitor with the molecular formula C22H27FN4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V99T50803M, chemically known as 1h-pyrrole-3-carboxamide, n-(2-(diethylamino)ethyl)-5-((z)-(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl)-2,4-dimethyl- but generally known as sunitinib, which bears US NIH Compound Identifier 5329102.

UNSPSC 51112009 Sunitinib is a Commodity code that covers a single pharmaceutical product — sunitinib, a tyrosine kinase inhibitor used in oncology and renal cell carcinoma treatment — but recent state and local procurement activity under this code reflects broader generic pharmaceutical sourcing. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, solicited manufacturers and distributors of generic multi-source pharmaceuticals and over-the-counter (OTC) products in January 2026, indicating that state and local governments use this code tier not to buy individual drugs but to establish standing contracts with pharmaceutical vendors serving multiple jurisdictions across their supply chains. The RFP requires vendors to supply products through three authorized wholesalers — AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC — and to certify compliance with current Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA). Vendors must maintain comprehensive insurance including workers' compensation, commercial general liability of $5,000,000 per occurrence, network security and privacy liability of $2,000,000, and professional liability of $2,000,000, and must demonstrate pricing flexibility through flat-price, net-price, or WAC-minus formats.

MMCAP is a multi-state cooperative vehicle administered by Minnesota but serving participating states including Oregon and other members. The RFP (S1070000015802) closed March 26, 2026, with a February 18, 2026 question cutoff, and awards are weighted 75 percent on price competitiveness, 10 percent on fixed pricing stability, and 15 percent on administrative compliance including EDI capability and a 3 percent administrative fee on all purchases. The resulting contracts are effective July 1, 2026, for a two-year term with optional extensions, and encompassing multiple awards is permitted based on therapeutic considerations and member-specific needs. No set-aside designations for small business, minority-owned, women-owned, or disadvantaged enterprise classifications are disclosed in the available solicitation materials.